This monthly feature will help readers keep current on new drugs, new indications, dosage forms, and safety-related changes in labeling or use. Efforts have been made to ensure the accuracy of this information; however, if there are any questions, please let me know at danial.baker@wsu.edu.
Treatment of patients with metastatic non-small-cell lung cancer (NSCLC) whose tumors express programmed death ligand 1 (PD-L1) as determined by an FDA-approved test, with disease progression on or after platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving pembrolizumab. (CONT.) (continued) Current FDA-Related Drug Information 
WARNINGS AND PRECAUTIONS Bone Fracture
• An increased risk of bone fracture, occurring as early as 12 weeks after treatment initiation, was observed in patients using canagliflozin.
ADVERSE REACTIONS Clinical Studies Experience Falls
• In a pool of 9 clinical trials with mean duration of exposure to canagliflozin of 85 weeks, the proportion of patients who experienced falls was 1.3%, 1.5%, and 2.1% with comparator, canagliflozin 100 mg, and canagliflozin 300 mg, respectively. The higher risk of falls for patients treated with canagliflozin was observed within the first few weeks of treatment.
(CONT.) (continued) Current FDA-Related Drug Information 
WARNINGS AND PRECAUTIONS Magnetic Resonance Imaging (MRI) Abnormalities in Infants
• Neurotoxicity and brain histopathological changes were observed in dogs exposed to vigabatrin during the juvenile period of development. .. Neurotoxicity
• Administration of vigabatrin to juvenile dogs produced vacuolar changes in the brain gray matter (including the septal nuclei, hippocampus, hypothalamus, thalamus, cerebellum, and globus pallidus). Neurobehavioral effects of vigabatrin were not assessed in the juvenile dog. http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm335401.htm a Practitioners are encouraged to check the US Food and Drug Administration's MedWatch Web site (http://www.fda.gov/medwatch/safety.htm) for updated information.
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